| Dr Steven Mark Zimmerman, MD | |
|
7700 E Parham Rd, Richmond, VA 23294-4301 | |
| (804) 747-5600 | |
| Not Available |
| Full Name | Dr Steven Mark Zimmerman |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 41 Years |
| Location | 7700 E Parham Rd, Richmond, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265432413 | NPI | - | NPPES |
| 006603823 | Medicaid | VA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 0101040351 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Henrico Doctors' Hospital | Richmond, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Forward Pathology Solutions, Llc | 2668703109 | 21 |
News Archive
HealthGrades, the nation's leading independent ratings organization, today made available to organ transplant patients a list of those hospitals with the best track record for survival and chances of receiving a donor organ. HealthGrades annual evaluation of the nation's top-performing hospitals in organ transplantation includes clinical quality data, based on patient outcomes, for each of the 210 adult acute care hospitals that perform transplants.
"At least one in five people worldwide were infected with swine flu during the first year of the 2009-2010 H1N1 pandemic, an international research group said on Friday, but the death rate was just 0.02 percent," Reuters reports.
For the past decade, researchers have tried to tweak cells at the gene and nucleus level to reprogram their identity.
Pfizer Inc. announced today that it has established a research collaboration with Medco Health Solutions, Inc. and its wholly owned subsidiary, United BioSource Corporation (UBC), aimed at more effectively matching patients with treatments that will benefit them the most, thereby improving patient outcomes.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
› Verified 7 days ago
| Entity Name | Commonwealth Laboratory Consultants Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942200555 PECOS PAC ID: 3870503139 Enrollment ID: O20060501000689 |
News Archive
HealthGrades, the nation's leading independent ratings organization, today made available to organ transplant patients a list of those hospitals with the best track record for survival and chances of receiving a donor organ. HealthGrades annual evaluation of the nation's top-performing hospitals in organ transplantation includes clinical quality data, based on patient outcomes, for each of the 210 adult acute care hospitals that perform transplants.
"At least one in five people worldwide were infected with swine flu during the first year of the 2009-2010 H1N1 pandemic, an international research group said on Friday, but the death rate was just 0.02 percent," Reuters reports.
For the past decade, researchers have tried to tweak cells at the gene and nucleus level to reprogram their identity.
Pfizer Inc. announced today that it has established a research collaboration with Medco Health Solutions, Inc. and its wholly owned subsidiary, United BioSource Corporation (UBC), aimed at more effectively matching patients with treatments that will benefit them the most, thereby improving patient outcomes.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
› Verified 7 days ago
| Entity Name | Forward Pathology Solutions, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982266391 PECOS PAC ID: 2668703109 Enrollment ID: O20191014002724 |
News Archive
HealthGrades, the nation's leading independent ratings organization, today made available to organ transplant patients a list of those hospitals with the best track record for survival and chances of receiving a donor organ. HealthGrades annual evaluation of the nation's top-performing hospitals in organ transplantation includes clinical quality data, based on patient outcomes, for each of the 210 adult acute care hospitals that perform transplants.
"At least one in five people worldwide were infected with swine flu during the first year of the 2009-2010 H1N1 pandemic, an international research group said on Friday, but the death rate was just 0.02 percent," Reuters reports.
For the past decade, researchers have tried to tweak cells at the gene and nucleus level to reprogram their identity.
Pfizer Inc. announced today that it has established a research collaboration with Medco Health Solutions, Inc. and its wholly owned subsidiary, United BioSource Corporation (UBC), aimed at more effectively matching patients with treatments that will benefit them the most, thereby improving patient outcomes.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Steven Mark Zimmerman, MD Po Box 5468, Martinsville, VA 24115-5468 Ph: () - | Dr Steven Mark Zimmerman, MD 7700 E Parham Rd, Richmond, VA 23294-4301 Ph: (804) 747-5600 |
News Archive
HealthGrades, the nation's leading independent ratings organization, today made available to organ transplant patients a list of those hospitals with the best track record for survival and chances of receiving a donor organ. HealthGrades annual evaluation of the nation's top-performing hospitals in organ transplantation includes clinical quality data, based on patient outcomes, for each of the 210 adult acute care hospitals that perform transplants.
"At least one in five people worldwide were infected with swine flu during the first year of the 2009-2010 H1N1 pandemic, an international research group said on Friday, but the death rate was just 0.02 percent," Reuters reports.
For the past decade, researchers have tried to tweak cells at the gene and nucleus level to reprogram their identity.
Pfizer Inc. announced today that it has established a research collaboration with Medco Health Solutions, Inc. and its wholly owned subsidiary, United BioSource Corporation (UBC), aimed at more effectively matching patients with treatments that will benefit them the most, thereby improving patient outcomes.
ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.
› Verified 7 days ago
Dr. Paul Weisz-carrington, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 1201 Broad Rock Blvd, 113, Richmond, VA 23249 Phone: 804-794-9396 | |
Dr. Beth Barton Hewitt, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 5801 Bremo Rd, Richmond, VA 23226 Phone: 804-281-8100 | |
Dr. Elaine Lizabeth Flanders, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 5801 Bremo Rd, Richmond, VA 23226 Phone: 804-281-8100 | |
Dr. Jennifer A Daniel-johnson, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 219 N 28th St, Richmond, VA 23223 Phone: 206-552-4889 | |
Dr. Harold Paul Dunn, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 5801 Bremo Rd, Richmond, VA 23226 Phone: 804-281-8100 | |
Dr. Susan D Roseff, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 1250 E Marshall Street, Pathology, Richmond, VA 23298 Phone: 804-828-9746 Fax: 804-828-9749 | |
Dr. Jonathan M Ben-ezra, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 1250 E Marshall Street, Pathology, Richmond, VA 23298 Phone: 804-828-0902 Fax: 804-828-2812 |